Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 8/20 | 0.56 |
| ▸ | IL1RN | P18510 | 1/20 | 0.54 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.54 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.54 |
| ▸ | CTSS | P25774 | 2/20 | 0.53 |
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | CTSB | P07858 | 1/20 | 0.53 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.51 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7119784 | 0.99 | CTSK (0.55) | CTSKIL1RNERAP2ERAP1CTSS | |
| Hydrochloric Acid SCHEMBL7581883 | 0.95 | CTSK (0.52) | CTSKIL1RNERAP2ERAP1CTSS | |
| SCHEMBL27824395 | 0.92 | CTSK (0.58) | CTSKCTSSCTSLCTSBS1PR4 | |
| SCHEMBL11209394 | 0.92 | CTSK (0.58) | CTSKCTSSCTSLCTSBS1PR4 | |
| SCHEMBL11680813 | 0.90 | LTA4H (0.57) | CTSKCTSB | |
| SCHEMBL22475577 | 0.90 | LTA4H (0.57) | CTSKCTSB | |
| SCHEMBL11682299 | 0.90 | LTA4H (0.57) | CTSKCTSB | |
| SCHEMBL20881521 | 0.90 | LTA4H (0.57) | CTSKCTSB | |
| SCHEMBL11683261 | 0.90 | LTA4H (0.57) | CTSKCTSB | |
| Hydrochloric Acid SCHEMBL11681832 | 0.89 | LTA4H (0.56) | CTSKCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262169-B1 | Process for preparing peptide intermediates | MERCK & CO., INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-20030133927-A1 | Conjugates useful in the treatment of prostate cancer | DEFEO-JONES DEBORAH (US) | 2003-07-17 | — | — | US | disclosed |
| US-6552166-B1 | Oligopeptide is mixed with a salt of the anthracycline antibiotic in the presence of a carboxyl activating agent and a base | MERCK & CO., INC. | 2003-04-22 | — | — | US | disclosed |
| EP-1228089-A2 | SALT FORM OF A CONJUGATE USEFUL IN THE TREATMENT OF PROSTATE CANCER | Merck & Co., Inc. (US) | 2002-08-07 | — | — | EP | disclosed |
| EP-1225918-A2 | CONJUGATES USEFUL IN THE TREATMENT OF PROSTATE CANCER | Merck & Co., Inc. (US) | 2002-07-31 | — | — | EP | disclosed |
| US-20020041880-A1 | Method of treating cancer | DEFEO-JONES DEBORAH (US) | 2002-04-11 | — | — | US | disclosed |
| US-20020042375-A1 | Method of treating cancer | HEIMBROOK DAVID C (US) | 2002-04-11 | — | — | US | disclosed |
| US-6355611-B1 | SODIUM SALT OF PROSTATE SPECIFIC ANTIGEN CONJUGATE COMPOUND; USEFUL IN TREATMENT OF PROSTATE CANCER AND BENIGN PROSTATIC HYPERPLASIA | MERCK & CO., INC. | 2002-03-12 | — | — | US | disclosed |
| WO-2001030804-A2 | SALT FORM OF A CONJUGATE USEFUL IN THE TREATMENT OF PROSTATE CANCER | MERCK & CO., INC. (US) | 2001-05-03 | — | — | WO | disclosed |
| WO-2001028593-A2 | CONJUGATES USEFUL IN THE TREATMENT OF PROSTATE CANCER | MERCK & CO., INC. (US) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030133927-A1 | Conjugates useful in the treatment of prostate cancer | BCL2, BCL2L10, BCL2L13 | CTSK 753/4885IL1RN 2449/4885ERAP2 308/4885 |
| US-20020042375-A1 | Method of treating cancer | ACP3, KLK3, FOLH1 | CTSK 624/4885IL1RN 2151/4885ERAP2 337/4885 |
| US-20020041880-A1 | Method of treating cancer | ACP3, FOLH1, KLK3 | CTSK 276/4885IL1RN 2919/4885ERAP2 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.